SG11201806982PA - Cinnolin-4-amine compounds and their use in treating cancer - Google Patents
Cinnolin-4-amine compounds and their use in treating cancerInfo
- Publication number
- SG11201806982PA SG11201806982PA SG11201806982PA SG11201806982PA SG11201806982PA SG 11201806982P A SG11201806982P A SG 11201806982PA SG 11201806982P A SG11201806982P A SG 11201806982PA SG 11201806982P A SG11201806982P A SG 11201806982PA SG 11201806982P A SG11201806982P A SG 11201806982PA
- Authority
- SG
- Singapore
- Prior art keywords
- compounds
- salts
- international
- astrazeneca
- pct
- Prior art date
Links
Classifications
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07D—HETEROCYCLIC COMPOUNDS
- C07D405/00—Heterocyclic compounds containing both one or more hetero rings having oxygen atoms as the only ring hetero atoms, and one or more rings having nitrogen as the only ring hetero atom
- C07D405/14—Heterocyclic compounds containing both one or more hetero rings having oxygen atoms as the only ring hetero atoms, and one or more rings having nitrogen as the only ring hetero atom containing three or more hetero rings
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K31/00—Medicinal preparations containing organic active ingredients
- A61K31/33—Heterocyclic compounds
- A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
- A61K31/495—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with two or more nitrogen atoms as the only ring heteroatoms, e.g. piperazine or tetrazines
- A61K31/50—Pyridazines; Hydrogenated pyridazines
- A61K31/502—Pyridazines; Hydrogenated pyridazines ortho- or peri-condensed with carbocyclic ring systems, e.g. cinnoline, phthalazine
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P35/00—Antineoplastic agents
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K31/00—Medicinal preparations containing organic active ingredients
- A61K31/16—Amides, e.g. hydroxamic acids
- A61K31/17—Amides, e.g. hydroxamic acids having the group >N—C(O)—N< or >N—C(S)—N<, e.g. urea, thiourea, carmustine
- A61K31/175—Amides, e.g. hydroxamic acids having the group >N—C(O)—N< or >N—C(S)—N<, e.g. urea, thiourea, carmustine having the group, >N—C(O)—N=N— or, e.g. carbonohydrazides, carbazones, semicarbazides, semicarbazones; Thioanalogues thereof
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K31/00—Medicinal preparations containing organic active ingredients
- A61K31/185—Acids; Anhydrides, halides or salts thereof, e.g. sulfur acids, imidic, hydrazonic or hydroximic acids
- A61K31/19—Carboxylic acids, e.g. valproic acid
- A61K31/195—Carboxylic acids, e.g. valproic acid having an amino group
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K31/00—Medicinal preparations containing organic active ingredients
- A61K31/33—Heterocyclic compounds
- A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
- A61K31/40—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having five-membered rings with one nitrogen as the only ring hetero atom, e.g. sulpiride, succinimide, tolmetin, buflomedil
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K31/00—Medicinal preparations containing organic active ingredients
- A61K31/33—Heterocyclic compounds
- A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
- A61K31/41—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having five-membered rings with two or more ring hetero atoms, at least one of which being nitrogen, e.g. tetrazole
- A61K31/4164—1,3-Diazoles
- A61K31/4184—1,3-Diazoles condensed with carbocyclic rings, e.g. benzimidazoles
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K31/00—Medicinal preparations containing organic active ingredients
- A61K31/33—Heterocyclic compounds
- A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
- A61K31/435—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with one nitrogen as the only ring hetero atom
- A61K31/47—Quinolines; Isoquinolines
- A61K31/4738—Quinolines; Isoquinolines ortho- or peri-condensed with heterocyclic ring systems
- A61K31/4745—Quinolines; Isoquinolines ortho- or peri-condensed with heterocyclic ring systems condensed with ring systems having nitrogen as a ring hetero atom, e.g. phenantrolines
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K31/00—Medicinal preparations containing organic active ingredients
- A61K31/66—Phosphorus compounds
- A61K31/675—Phosphorus compounds having nitrogen as a ring hetero atom, e.g. pyridoxal phosphate
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K31/00—Medicinal preparations containing organic active ingredients
- A61K31/70—Carbohydrates; Sugars; Derivatives thereof
- A61K31/7028—Compounds having saccharide radicals attached to non-saccharide compounds by glycosidic linkages
- A61K31/7034—Compounds having saccharide radicals attached to non-saccharide compounds by glycosidic linkages attached to a carbocyclic compound, e.g. phloridzin
- A61K31/704—Compounds having saccharide radicals attached to non-saccharide compounds by glycosidic linkages attached to a carbocyclic compound, e.g. phloridzin attached to a condensed carbocyclic ring system, e.g. sennosides, thiocolchicosides, escin, daunorubicin
Applications Claiming Priority (2)
Application Number | Priority Date | Filing Date | Title |
---|---|---|---|
US201662310883P | 2016-03-21 | 2016-03-21 | |
PCT/EP2017/056592 WO2017162605A1 (fr) | 2016-03-21 | 2017-03-20 | Composés cinnolin-4-amine et leur utilisation pour traiter le cancer |
Publications (1)
Publication Number | Publication Date |
---|---|
SG11201806982PA true SG11201806982PA (en) | 2018-09-27 |
Family
ID=58361025
Family Applications (1)
Application Number | Title | Priority Date | Filing Date |
---|---|---|---|
SG11201806982PA SG11201806982PA (en) | 2016-03-21 | 2017-03-20 | Cinnolin-4-amine compounds and their use in treating cancer |
Country Status (18)
Country | Link |
---|---|
US (1) | US20190099421A1 (fr) |
EP (1) | EP3433251A1 (fr) |
JP (1) | JP2019512512A (fr) |
KR (1) | KR20180127419A (fr) |
CN (1) | CN108884084A (fr) |
AR (1) | AR107937A1 (fr) |
AU (1) | AU2017237394A1 (fr) |
BR (1) | BR112018068347A2 (fr) |
CA (1) | CA3017035A1 (fr) |
CO (1) | CO2018010951A2 (fr) |
DO (1) | DOP2018000197A (fr) |
IL (1) | IL261648A (fr) |
MA (1) | MA43733A (fr) |
MX (1) | MX2018011283A (fr) |
PE (1) | PE20181895A1 (fr) |
SG (1) | SG11201806982PA (fr) |
TW (1) | TW201808939A (fr) |
WO (1) | WO2017162605A1 (fr) |
Families Citing this family (4)
Publication number | Priority date | Publication date | Assignee | Title |
---|---|---|---|---|
WO2019057757A1 (fr) * | 2017-09-20 | 2019-03-28 | Astrazeneca Ab | Composés 1,3-dihydroimidazo[4,5-c]cinnolin-2-one et leur utilisation dans le traitement du cancer |
US20210353614A1 (en) * | 2018-03-14 | 2021-11-18 | Merck Patent Gmbh | Compounds and uses thereof to treat tumors in a subject |
EP3849984A4 (fr) | 2018-09-14 | 2022-06-01 | Suzhou Zanrong Pharma Limited | 1-isopropyl-3-méthyl-8- (pyridin-3-yl) -1, 3-dihydro-2h-imidazo [4, 5-c] cinnolin-2-one servant de modulateurs sélectifs de la kinase ataxie télangiectasie (atm) mutée et utilisations associées |
WO2021260580A1 (fr) | 2020-06-24 | 2021-12-30 | Astrazeneca Uk Limited | Combinaison d'un conjugué anticorps-médicament et d'un inhibiteur de l'atm |
Family Cites Families (8)
Publication number | Priority date | Publication date | Assignee | Title |
---|---|---|---|---|
GB9624482D0 (en) | 1995-12-18 | 1997-01-15 | Zeneca Phaema S A | Chemical compounds |
IL125686A (en) | 1996-02-13 | 2002-11-10 | Zeneca Ltd | Quinazoline derivatives, processes for their preparation, pharmaceutical preparations containing them and their use in the manufacture of a drug with an anti-angiogenic effect and / or an effect of reducing vascular permeability |
DE69709319T2 (de) | 1996-03-05 | 2002-08-14 | Astrazeneca Ab | 4-anilinochinazolin derivate |
GB9718972D0 (en) | 1996-09-25 | 1997-11-12 | Zeneca Ltd | Chemical compounds |
CL2008000191A1 (es) * | 2007-01-25 | 2008-08-22 | Astrazeneca Ab | Compuestos derivados de 4-amino-cinnotina-3-carboxamida; inhibidores de csf-1r quinasa; su proceso de preparacion; y su uso para tratar el cancer. |
EP2668162A1 (fr) | 2011-01-28 | 2013-12-04 | Novartis AG | Composés bi-hétéroaryles substitués en tant qu'inhibiteurs de cdk9 et leurs utilisations |
EP2726465A1 (fr) * | 2011-05-23 | 2014-05-07 | Elan Pharmaceuticals Inc. | Inhibiteurs de l'activité lrrk2 kinase |
NO2714752T3 (fr) * | 2014-05-08 | 2018-04-21 |
-
2017
- 2017-03-20 CN CN201780017874.XA patent/CN108884084A/zh active Pending
- 2017-03-20 KR KR1020187030086A patent/KR20180127419A/ko unknown
- 2017-03-20 AU AU2017237394A patent/AU2017237394A1/en not_active Abandoned
- 2017-03-20 MX MX2018011283A patent/MX2018011283A/es unknown
- 2017-03-20 BR BR112018068347A patent/BR112018068347A2/pt not_active IP Right Cessation
- 2017-03-20 MA MA043733A patent/MA43733A/fr unknown
- 2017-03-20 WO PCT/EP2017/056592 patent/WO2017162605A1/fr active Application Filing
- 2017-03-20 JP JP2018549311A patent/JP2019512512A/ja active Pending
- 2017-03-20 US US16/086,742 patent/US20190099421A1/en not_active Abandoned
- 2017-03-20 SG SG11201806982PA patent/SG11201806982PA/en unknown
- 2017-03-20 PE PE2018001829A patent/PE20181895A1/es not_active Application Discontinuation
- 2017-03-20 TW TW106109172A patent/TW201808939A/zh unknown
- 2017-03-20 CA CA3017035A patent/CA3017035A1/fr not_active Abandoned
- 2017-03-20 EP EP17712123.3A patent/EP3433251A1/fr not_active Withdrawn
- 2017-03-21 AR ARP170100697A patent/AR107937A1/es unknown
-
2018
- 2018-09-06 IL IL261648A patent/IL261648A/en unknown
- 2018-09-18 DO DO2018000197A patent/DOP2018000197A/es unknown
- 2018-10-12 CO CONC2018/0010951A patent/CO2018010951A2/es unknown
Also Published As
Publication number | Publication date |
---|---|
US20190099421A1 (en) | 2019-04-04 |
MA43733A (fr) | 2018-11-28 |
TW201808939A (zh) | 2018-03-16 |
EP3433251A1 (fr) | 2019-01-30 |
WO2017162605A1 (fr) | 2017-09-28 |
PE20181895A1 (es) | 2018-12-11 |
AU2017237394A1 (en) | 2018-11-01 |
CA3017035A1 (fr) | 2017-09-28 |
MX2018011283A (es) | 2019-05-27 |
AR107937A1 (es) | 2018-06-28 |
KR20180127419A (ko) | 2018-11-28 |
CN108884084A (zh) | 2018-11-23 |
BR112018068347A2 (pt) | 2019-01-15 |
IL261648A (en) | 2018-10-31 |
CO2018010951A2 (es) | 2018-10-22 |
JP2019512512A (ja) | 2019-05-16 |
DOP2018000197A (es) | 2018-10-15 |
Similar Documents
Publication | Publication Date | Title |
---|---|---|
SG11201805300QA (en) | Heterocyclic compounds as immunomodulators | |
SG11201903182XA (en) | 6,7,8,9-tetrahydro-3h-pyrazolo[4,3-f]isoquinoline derivatives useful in the treatment of cancer | |
SG11201804373VA (en) | Compositions and methods for immunooncology | |
SG11201805044WA (en) | Compounds useful as kinase inhibitors | |
SG11201804901WA (en) | Compounds for the treatment of cancer and inflammatory disease | |
SG11201902938TA (en) | Compounds, devices, and uses thereof | |
SG11201803686UA (en) | Prodrugs of a jak inhibitor compound for treatment of gastrointestinal inflammatory disease | |
SG11201803920TA (en) | Compounds and compositions useful for treating disorders related to ntrk | |
SG11201407580YA (en) | Composition comprising two antibodies engineered to have reduced and increased effector function | |
SG11201807809XA (en) | A transient commensal microorganism for improving gut health | |
SG11201808566WA (en) | Polymorphic form of n-{6-(2-hydroxypropan-2-yl)-2-[2-(methylsulphonyl)ethyl]-2h-indazol-5-yl}-6-(trifluoromethyl)pyridine-2-carboxamide | |
SG11201908065YA (en) | Deuterated imidazo[4,5-c]quinolin-2-one compounds and their use in treating cancer | |
SG11201809908TA (en) | Stabilized glycopeptide antibiotic formulations | |
SG11201804704PA (en) | Compositions and methods for decreasing tau expression | |
SG11201908602UA (en) | Combination therapy for the treatment of solid and hematological cancers | |
SG11201804587QA (en) | Isoindole compounds | |
SG11201906222WA (en) | Jak1 selective inhibitors | |
SG11201806982PA (en) | Cinnolin-4-amine compounds and their use in treating cancer | |
SG11201908691PA (en) | Compounds and methods for the treatment of parasitic diseases | |
SG11201906767XA (en) | Estrogen receptor modulators | |
SG11201901063SA (en) | Therapeutic agents for neurodegenerative diseases | |
SG11201807523PA (en) | Ilt7 binding molecules and methods of using the same | |
SG11201408509PA (en) | Racecadotril lipid compositions | |
SG11201806424TA (en) | Therapeutic compounds | |
SG11201810940XA (en) | Methods of treating pancreatic cancer |